These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 24754910)

  • 1. How good are ensembles in improving QSAR models? The case with eCoRIA.
    Khedkar VM; Joseph J; Pissurlenkar R; Saran A; Coutinho EC
    J Biomol Struct Dyn; 2015; 33(4):749-69. PubMed ID: 24754910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CoRILISA: a local similarity based receptor dependent QSAR method.
    Khedkar VM; Coutinho EC
    J Chem Inf Model; 2015 Jan; 55(1):194-205. PubMed ID: 25535645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes.
    da Cunha EF; Sippl W; de Castro Ramalho T; Ceva Antunes OA; de Alencastro RB; Albuquerque MG
    Eur J Med Chem; 2009 Nov; 44(11):4344-52. PubMed ID: 19616874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
    Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
    Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results.
    Opera TI; Waller CL; Marshall GR
    Drug Des Discov; 1994 Jul; 12(1):29-51. PubMed ID: 7578806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ensemble QSAR: a QSAR method based on conformational ensembles and metric descriptors.
    Pissurlenkar RR; Khedkar VM; Iyer RP; Coutinho EC
    J Comput Chem; 2011 Jul; 32(10):2204-18. PubMed ID: 21509786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LQTA-QSAR: a new 4D-QSAR methodology.
    Martins JP; Barbosa EG; Pasqualoto KF; Ferreira MM
    J Chem Inf Model; 2009 Jun; 49(6):1428-36. PubMed ID: 19422246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design.
    Pérez C; Pastor M; Ortiz AR; Gago F
    J Med Chem; 1998 Mar; 41(6):836-52. PubMed ID: 9526559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
    Hou T; Zhu L; Chen L; Xu X
    J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based and multiple potential three-dimensional quantitative structure-activity relationship (SB-MP-3D-QSAR) for inhibitor design.
    Du QS; Gao J; Wei YT; Du LQ; Wang SQ; Huang RB
    J Chem Inf Model; 2012 Apr; 52(4):996-1004. PubMed ID: 22480344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies of N(9)-arenthenyl purines as novel DFG-in and DFG-out dual Src/Abl inhibitors using 3D-QSAR, docking and molecular dynamics simulations.
    Ma S; Zeng G; Fang D; Wang J; Wu W; Xie W; Tan S; Zheng K
    Mol Biosyst; 2015 Feb; 11(2):394-406. PubMed ID: 25406390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating Multiple Receptor Conformation Docking and Multi Dimensional QSAR for Enhancing Accuracy of Binding Affinity Prediction.
    Radhika V; Jaraf HA; Kanth SS; Vijjulatha M
    Curr Comput Aided Drug Des; 2017; 13(2):127-142. PubMed ID: 28103770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive analysis of the thermodynamic events involved in ligand-receptor binding using CoRIA and its variants.
    Verma J; Khedkar VM; Prabhu AS; Khedkar SA; Malde AK; Coutinho EC
    J Comput Aided Mol Des; 2008 Feb; 22(2):91-104. PubMed ID: 18219446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empirical free energy calculations of human immunodeficiency virus type 1 protease crystallographic complexes. II. Knowledge-based ligand-protein interaction potentials applied to thermodynamic analysis of hydrophobic mutations.
    Verkhivker GM
    Pac Symp Biocomput; 1996; ():638-52. PubMed ID: 9390264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Free-energy force-field three-dimensional quantitative structure-activity relationship analysis of a set of p38-mitogen activated protein kinase inhibitors.
    Romeiro NC; Albuquerque MG; de Alencastro RB; Ravi M; Hopfinger AJ
    J Mol Model; 2006 Sep; 12(6):855-68. PubMed ID: 16541250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative residue interaction analysis (CoRIA): a 3D-QSAR approach to explore the binding contributions of active site residues with ligands.
    Datar PA; Khedkar SA; Malde AK; Coutinho EC
    J Comput Aided Mol Des; 2006 Jun; 20(6):343-60. PubMed ID: 17009094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of ligand-receptor binding thermodynamics by free energy force field three-dimensional quantitative structure-activity relationship analysis: applications to a set of glucose analogue inhibitors of glycogen phosphorylase.
    Venkatarangan P; Hopfinger AJ
    J Med Chem; 1999 Jun; 42(12):2169-79. PubMed ID: 10377222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
    Halder AK; Saha A; Saha KD; Jha T
    J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
    Zhang G; Ren Y
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.